Q-omics provides the consensus-scored DNAJA3 profile across patient tissues and cancer cell-line models. DNAJA3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, DNAJA3 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, DNAJA3 protein abundance shows 31,137 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight PAAD, COAD, and LSCC as cancer lineages where DNAJA3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNAJA3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNAJA3 survival associations across molecular data types. DNAJA3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNAJA3 RNA expression–survival associations across cancer types. High DNAJA3 expression shows unfavorable associations in PAAD, LGG, BLCA, HNSC, CHOL and UVM. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for DNAJA3 RNA expression.
This table summarizes DNAJA3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 8. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DNAJA3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNAJA3 shows higher tumor expression in COAD, KIRP, LUAD, STAD, LUSC and HNSC. The COAD box plot shows higher DNAJA3 RNA expression in tumor versus normal tissue (log2 FC = +1.096, t-test p < 0.001).
This table shows molecular features associated with DNAJA3 in patient tissues and cancer cell lines. In patient samples, DNAJA3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, DNAJA3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and UPPER_AERODIGESTIVE_TRACT.
